Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Verified January 2014 by University of Iowa
Holden Comprehensive Cancer Center
Information provided by (Responsible Party):
Milhem, Mohammed M, University of Iowa
First received: June 18, 2009
Last updated: January 13, 2014
Last verified: January 2014
The purpose of this study is to treat metastatic melanoma with a combination of standard chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug called panobinostat. This combination is proposed to unlock genes that may contribute to mechanisms that cause tumor growth.
The primary objectives of this study are:
- To evaluate the safety and tolerability of the proposed schedule of decitabine, temozolomide and panobinostat in the treatment of metastatic melanoma.
- To define any Dose Limiting Toxicity (DLT) and maximum tolerated dose (MTD) of the combination of decitabine, temozolomide and panobinostat.
Drug: Temozolomide, Decitabine, Panobinostat
||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase Ib/II: Epigenetic Modification of Chemosensitivity and Apoptosis in Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine, Temozolomide and Panobinostat
Primary Outcome Measures:
- Phase I - to evaluate the safety and tolerability of the proposed schedule of decitabine, temozolomide and panobinostat in the treatment of metastatic melanoma. [ Time Frame: 15 months ] [ Designated as safety issue: Yes ]
- Phase 2 - To measure the time to progression of patients treated with this combination in comparison to patients treated historically with DTIC (the current standard of care). [ Time Frame: 3-4 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Phase I - to define the dose limiting toxicity and maximum tolerated dose of the combination of decitabine, temozolomide and panobinostat. [ Time Frame: 15 months ] [ Designated as safety issue: No ]
- Phase 2 - to measure overall survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Phase 2 - to evaluate treatment response with FDG pET and compare FDG PET with conventional imaging for treatment response assessment. [ Time Frame: 3-4 years ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2016 (Final data collection date for primary outcome measure)
Drug: Temozolomide, Decitabine, Panobinostat
Temozolomide - given each cycle.
Decitabine - 6 cohorts with dose escalation.
Panobinostat - 6 cohorts with dose escalation.
Other Name: LBH589
Most chemotherapeutics target rapidly proliferating cells, leaving quiescent cells and those with extended cell cycles unaffected. The investigators propose that this combination of decitabine, temozolomide, and panobinostat will target both melanoma stem cells and rapidly proliferating melanoma cells. The use of two drugs that regulate gene expression epigenetically (panobinostat and decitabine) in combination with a chemotherapeutic agent (temozolomide) is hypothesized to:
- induce expression genes (e.g., Apaf-1) that increase chemosensitivity of tumor cells and enhance apoptosis
- potentiate the cytotoxic effect of temozolomide by epigenetic modulation, and
- induce proliferation and differentiation of tumor stem cells, thus enabling senescence and apoptosis.
- To measure overall survival
- To measure the time to progression of patients treated with this combination in comparison to patients treated historically with DTIC (the current standard of care).
- To evaluate treatment response with FDG PET and compare FDG PET with conventional imaging for treatment response assessment.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female patients aged ≥ 18 years old
- ECOG Performance Status of ≤ 2
- Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- Patients must have measurable disease according to RECIST and CHOI criteria. The minimum target-lesion diameter should have double the CT slice thickness, i.e., 10 mm
Patients must meet the following laboratory criteria:
Hematology: Neutrophil count of >1500/mm3;Platelet count of > 100,000/mm3L; Hemoglobin ≥ 9 g/dL Biochemistry:AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x upper limit of normal if the transaminase elevation is due to disease involvement;Serum bilirubin ≤ 1.5 x upper limit of normal;Serum creatinine ≤ 1.5 x upper limit of normal or 24-hour creatinine clearance ≥ 50 ml/min; Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal; Serum potassium ≥ lower limit of normal; Serum sodium ≥ lower limit of normal;Serum albumin ≥ lower limit of normal or 3g/dl;Patients with any elevated alkaline phosphatase due to bone metastasis can be enrolled
- Baseline ECHO must demonstrate LVEF ≥ the lower limit of the institutional normal.
- TSH and free T4 within normal limits (patients may be on thyroid hormone replacement)
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 8 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method during the study and for 3 months after last study drug administration
- Any patient with the diagnosis of metastatic melanoma from any site. These include untreated patients or those treated with chemotherapy or biochemotherapy.
- Must not have taken a hypomethylating agent or a histone deacetylase agent in the treatment of their disease.
- Any patient with metastatic melanoma regardless of prior treatment will be eligible.
- Patients must have had disease progression on or following their most recent treatment regimen or on presentation for the first time with metastatic disease, surgical option can be entertained if this is a localized relapse.
- Patients with CNS disease are eligible for treatment only after their CNS disease has been directly addressed with radiation therapy.
- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment
- Impaired cardiac function including any one of the following: Screening ECG with a QTc > 450 msec confirmed by central laboratory prior to enrollment to the study; Patients with congenital long QT syndrome; History of sustained ventricular tachycardia; Any history of ventricular fibrillation or torsades de pointes; Bradycardia defined as heart rate < 50 beats per minute. Patients with a pacemaker and heart rate ≥ 50 beats per minute are eligible; Patients with a myocardial infarction or unstable angina within 6 months of study entry; Congestive heart failure (NY Heart Association class III or IV);Right bundle branch block and left anterior hemiblock (bifascicular block)
- Uncontrolled hypertension
- Concomitant use of drugs with a risk of causing torsades de pointes
- Concomitant use of CYP3A4 inhibitors
- Patients with unresolved diarrhea > CTCAE grade 1
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat
- Other concurrent severe and/or uncontrolled medical conditions
- Patients who have received chemotherapy, any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- Concomitant use of any anti-cancer therapy or radiation therapy.
- Patients who have no measurable disease.
- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months(i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 8 days of the first administration of oral panobinostat.
- Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom
- Patients with a history of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin
- Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
- Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00925132
|University of Iowa Hospitals and Clinics
|Iowa City, Iowa, United States, 52242 |
|Principal Investigator: Mohammed Milhem, MD |
University of Iowa
Holden Comprehensive Cancer Center
No publications provided by University of Iowa
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
||Milhem, Mohammed M, Clinical Associate Professor, University of Iowa
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 18, 2009
||January 13, 2014
||United States: Food and Drug Administration
Keywords provided by University of Iowa:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 03, 2015
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Alkylating
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action